aztreonam has been researched along with cefotetan in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (26.32) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jolivette, LJ; Ward, KW | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Kanamori, M; Kirikae, T; Kitao, T; Miyoshi-Akiyama, T; Morita, K; Okazaki, M; Sekiguchi, J; Watanabe, N | 1 |
| Arakawa, Y; Ishikawa, K; Nagano, N; Nagano, Y; Wachino, J | 1 |
| Baptista, BC; Correia, JD; da Fonseca, JD; MartÃnez-MartÃnez, L; Pomba, C | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Borgianni, L; Docquier, JD; Hanson, ND; Prandi, S; Rossolini, GM; Salden, L; Santella, G | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Flink, JR; Heaton, AH; Wagner, BK | 1 |
| Bellantone, R; Bossola, M; Crucitti, F; Doglietto, GB; Pacelli, F; Ratto, C; Sofo, L | 1 |
| Cocuzza, CE; Mattina, R; Raimondi, A | 1 |
| Fournier, P; Labia, R; Morand, A; Philippin, JL; Pitton, JS | 1 |
| Harvengt, C | 1 |
| Edmondson, RA; Reading, C | 1 |
| Dodson, MG | 1 |
2 review(s) available for aztreonam and cefotetan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antibiotic regimens for treating acute pelvic inflammatory disease. An evaluation.
Topics: Acute Disease; Anti-Bacterial Agents; Aztreonam; Cefotetan; Cefoxitin; Chlamydia Infections; Chlamydia trachomatis; Clindamycin; Drug Evaluation; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Gentamicins; Humans; Pelvic Inflammatory Disease; Tetracycline Resistance | 1994 |
1 trial(s) available for aztreonam and cefotetan
| Article | Year |
|---|---|
Systemic perioperative prophylaxis in elective oncological colorectal surgery: cefotetan versus clindamicin plus aztreonam.
Topics: Adult; Aged; Aged, 80 and over; Aztreonam; Cefotetan; Clindamycin; Colorectal Neoplasms; Female; Humans; Infection Control; Infections; Male; Middle Aged; Postoperative Complications; Surgical Wound Infection | 1988 |
16 other study(ies) available for aztreonam and cefotetan
| Article | Year |
|---|---|
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
Topics: Anti-Bacterial Agents; Cephalosporinase; Culture Media; DNA Primers; Drug Resistance, Bacterial; Escherichia coli; Kinetics; Models, Molecular; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Spectrophotometry, Ultraviolet | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
Topics: Amino Acid Sequence; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Citrobacter freundii; Conjugation, Genetic; DNA Primers; DNA, Bacterial; Enterobacteriaceae Infections; Escherichia coli K12; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Plasmids; Recombinant Proteins; Sequence Homology, Amino Acid | 2008 |
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
Topics: Amino Acid Sequence; beta-Lactamases; Blotting, Southern; Ceftazidime; Cephalosporins; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Polymerase Chain Reaction; Sequence Homology, Amino Acid; Shigella sonnei | 2009 |
Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
Topics: Animals; Anti-Bacterial Agents; Dogs; Drug Resistance, Bacterial; Escherichia coli; Genes, Bacterial; Humans; Plasmids; Virulence | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
Topics: Amino Acid Sequence; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ertapenem; Meropenem; Microbial Sensitivity Tests; Models, Genetic; Molecular Sequence Data; Open Reading Frames; Pseudomonas aeruginosa; Sequence Homology, Amino Acid; Thienamycins; United States | 2011 |
Cefotetan disodium-induced hemolytic anemia.
Topics: Anemia, Hemolytic; Aztreonam; Cefotetan; Clindamycin; Female; Humans; Injections, Intravenous; Middle Aged; Plasmapheresis | 1992 |
Carumonam's in-vitro activity against gram-negative bacteria and its stability to their beta-lactamases.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Cefotaxime; Cefotetan; Ceftazidime; Ceftriaxone; Cephamycins; Drug Stability; Gram-Negative Bacteria; Microbial Sensitivity Tests | 1988 |
[Effects of beta-lactamases on the antibacterial activity of carumonam and aztreonam against Klebsiella sp. in comparison with 4 other beta-lactams].
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Cefotaxime; Cefotetan; Cefoxitin; Cephamycins; Imipenem; Klebsiella; Klebsiella pneumoniae; Plasmids; Thienamycins | 1987 |
Drugs recently released in Belgium: aztreonam, cefotetan, cefonicid.
Topics: Aztreonam; Cefamandole; Cefonicid; Cefotetan; Cephamycins; Humans | 1986 |
Beta-lactamase stability of temocillin.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Cefotaxime; Cefotetan; Cephamycins; Chromosomes, Bacterial; In Vitro Techniques; Penicillins; Plasmids | 1985 |